Simulations Plus (NASDAQ:SLP) Trading Down 3.4% – Should You Sell?

Simulations Plus, Inc. (NASDAQ:SLP) dropped 3.4% during trading on Tuesday . The company traded as low as $30.11 and last traded at $30.29. Approximately 40,988 shares changed hands during trading, a decline of 81% from the average daily volume of 211,172 shares. The stock had previously closed at $31.34.

Analyst Upgrades and Downgrades

Several brokerages have commented on SLP. KeyCorp boosted their price target on shares of Simulations Plus from $32.00 to $40.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 16th. StockNews.com raised shares of Simulations Plus from a “sell” rating to a “hold” rating in a research note on Monday, April 28th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.00.

Simulations Plus Stock Performance

The stock has a 50-day moving average of $29.15 and a 200 day moving average of $30.31. The firm has a market capitalization of $637.42 million, a P/E ratio of 79.24 and a beta of 1.10.

Simulations Plus (NASDAQ:SLP) last released its quarterly earnings results on Thursday, April 3rd. The technology company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.25 by $0.06. The business had revenue of $22.43 million for the quarter, compared to analysts’ expectations of $21.93 million. Simulations Plus had a net margin of 10.97% and a return on equity of 6.84%. Simulations Plus’s revenue was up 22.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.20 earnings per share. On average, equities analysts predict that Simulations Plus, Inc. will post 1.09 EPS for the current year.

Insider Activity at Simulations Plus

In other news, Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $33.51, for a total value of $670,200.00. Following the sale, the director now owns 3,344,157 shares of the company’s stock, valued at $112,062,701.07. The trade was a 0.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 19.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of SLP. Proficio Capital Partners LLC acquired a new stake in Simulations Plus during the 4th quarter worth approximately $719,000. JPMorgan Chase & Co. lifted its holdings in shares of Simulations Plus by 106.0% during the third quarter. JPMorgan Chase & Co. now owns 47,365 shares of the technology company’s stock worth $1,517,000 after buying an additional 24,371 shares in the last quarter. Sei Investments Co. bought a new stake in shares of Simulations Plus in the fourth quarter valued at about $330,000. Tributary Capital Management LLC grew its stake in shares of Simulations Plus by 21.7% in the fourth quarter. Tributary Capital Management LLC now owns 396,093 shares of the technology company’s stock valued at $11,047,000 after acquiring an additional 70,526 shares in the last quarter. Finally, AlphaQuest LLC raised its stake in Simulations Plus by 502.9% in the 4th quarter. AlphaQuest LLC now owns 2,689 shares of the technology company’s stock worth $75,000 after purchasing an additional 2,243 shares in the last quarter. 78.08% of the stock is currently owned by institutional investors and hedge funds.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.